274 related articles for article (PubMed ID: 35884893)
1. PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Tang G; Fan G; Xu J
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884893
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
4. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
Fisher KE; Ferguson LS; Coffey AM; Merritt BY; Curry JL; Marcogliese AN; Major AM; Kamdar KY; Lopez-Terrada DH; Curry CV
Haematologica; 2022 Aug; 107(8):1880-1890. PubMed ID: 35081690
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
9.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
12. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
Satou A; Nakamura S
Cancer Med; 2021 Oct; 10(19):6777-6785. PubMed ID: 34387382
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
14. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA
Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
17. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
19. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
[TBL] [Abstract][Full Text] [Related]
20. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
